A review of new approaches in Her-2 targeting and 1H MRI application

被引：0
作者：
Dorota Bartusik
David Aebisher
Boguslaw Tomanek
机构：
[1] Southern Polytechnic State University,Department of Biology and Chemistry
[2] Cross Cancer Institute,Department of Medical Physics
[3] Shorter University,Natural Sciences Department
[4] University of Calgary,Department of Clinical Neurosciences and Radiology
[5] Polish Academy of Sciences,Institute of Nuclear Physics
来源：
Medicinal Chemistry Research | 2015年 / 24卷
关键词：
Magnetic resonance imaging; Breast cancer; Her-2 receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
To date, the Her-2 receptor is the most frequently detected breast cancer biomarker which can be monitored on the surface of tumors by proton magnetic resonance imaging (1H MRI). In the past decade, we observed major advances in the development of 1H MRI as a diagnostic tool in cancer studies. 1H MRI is noninvasive method and can be used to explore tumor biology, cancer cell surface morphology and provide information about drug efficacy, absorption, distribution, and elimination. This review describes current studies of Her-2 targeting with trastuzumab and the application of 1H MRI to Her-2 receptor detection.
引用
收藏
页码：1365 / 1368
页数：3
相关论文
共 323 条
[1]  
Adolphi NL(2012)Imaging of Her-2 targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI Contrast Media Mol Imaging 7 308-319
[2]  
Butler KS(2003)MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles Magn Reson Med 49 403-408
[3]  
Lovato DM(2012)Detection of trastuzumab efficacy using Med Chem Res 21 2316-2319
[4]  
Tessier TE(2001)H MRI ex vivo of breast cancer cells Eur J Cancer 37 S18-S24
[5]  
Trujillo JE(1996)Clinical trials of herceptin J Clin Oncol 14 737-744
[6]  
Hathaway HJ(1984)Phase II study of weekly intravenous recombinant humanized anti-p185 Her-2 monoclonal antibody in patients with Her-2/neu-overexpressing metastatic breast cancer Med Phys 11 425-448
[7]  
Fegan DL(2001)A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1–100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age J Clin Oncol 19 2722-2730
[8]  
Monson TC(1986)Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer J Neuro Oncol 3 315-321
[9]  
Stevens TE(2014) and Gastroenterology S0016–5085 00192-09005
[10]  
Huber DL(1999) proton nuclear magnetic resonance relaxation times in vitro and human intracranial tumours J Clin Oncol 17 2639-2648
12345678910